CompletedNCT00223496
12- Week Open Label Treatment of Refractory Depression in bipolarity
Medication studyAges 18–75United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- San AntonioSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 32
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00223496
- Official title
Show the full official title
12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP)
Get this study by email
Recruitment & locations
CompletedSan Antonio
Questions about this study
Who is behind this study?
The study sponsor is The University of Texas Health Science Center at San Antonio, a university.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 18 years to 75 years.
